



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86151

Takeshi KOIZUMI et al

Appln. No.: 10/524,860

Group Art Unit: Unknown

Confirmation No.: 2817

Examiner: Unknown

Filed: February 18, 2005

For: PRIMER AND PROBE FOR DETECTING *Vibrio vulnificus* AND DETECTION
METHOD USING THE SAME

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This response is in regard to the NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, dated July 14, 2005,
issued in the above-referenced patent application.

The Notification to Comply indicates that the present application fails to comply with the
requirements of 37 C.F.R. §§1.821-1.825. The Examiner further states that Applicants must
provide (1) a substitute computer readable form of the Sequence Listing as required by 37
C.F.R. § 1.821(e), and (2) a statement that the content of the sequence listing information

recorded in computer readable form is identical to the written, paper version of the sequence listing information.

Accordingly, Applicants include herewith a paper copy and computer readable form of a substitute Sequence Listing that is in full compliance with 37 C.F.R. § 1.825(d), a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825, and a copy of the Notification to Comply.

Applicants respectfully request entry of the substitute Sequence Listing into the pending application.

Applicants assert that this Response to the Notification to Comply and the enclosures are being timely filed, and that the enclosures bring the present application in full compliance with the requirements of 37 C.F.R. §§1.821-1.825.

Applicants respectfully request that the Examiner acknowledge that the Substitute Sequence Listing in the present application meets the requirements of 37 C.F.R. §§1.821-1.825.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Mark L. Hayman
Registration No. 51,793

Date: September 26, 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/524,860	FIRST NAMED APPLICANT Takeshi Koizumi	ATTY. DOCKET NO. Q86151
---	--	----------------------------

INTERNATIONAL APPLICATION NO.

PCT/JP03/10846

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

08/27/2003

08/30/2002

23373
 SUGHRUE MION, PLLC
 2100 PENNSYLVANIA AVENUE, NW
 SUITE 800
 WASHINGTON, DC 20037

DOCKETED

JUL 18 2005

CONFIRMATION NO. 2817

371 FORMALITIES LETTER



OC000000016509129

Date Mailed: 07/14/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/524,860	PCT/JP03/10846	Q86151

FORM PCT/DO/EO/922 (371 Formalities Notice)